Stanford’s Experimental Lymphedema Drug: What Two Acebilustat Studies Actually Tell Us

This is research education, not medication coaching or personal treatment advice.

For people living with lymphedema, long-term care can mean ongoing compression, self-care, physical care costs, and difficulty finding consistent support. An oral treatment option is understandably compelling, especially when access to care is limited. And right now, there is a real, published signal worth understanding honestly.

Core & Curve Lab evidence grade: emerging, not definitive. One published Stanford study reported meaningful reductions in measured limb volume over a year in a small group with Stage II lymphedema — while participants continued their usual compression and self-care. A second, placebo-controlled Stanford study of arm lymphedema exists; Stanford reported on September 30, 2026 that its results were being analyzed, and no published results report had been independently verified in this review as of October 25, 2026.

If you live with Stage 3–4 Lipedema or lipo-lymphedema, there is genuinely useful information here — and important limits about what these studies did, and did not, include.

What is acebilustat?

Acebilustat is an experimental oral drug that inhibits an enzyme called leukotriene A4 hydrolase. The enzyme plays a role in producing leukotriene B4, a molecule involved in inflammation. Researchers are investigating whether changing this pathway could affect lymphedema.

That is the proposed biological rationale, not proof of a clinical benefit. Acebilustat has not been authorized as a marketed treatment for lymphedema. FDA permission to use an investigational drug under a clinical-trial or expanded-access pathway is not marketing approval (FDA expanded access information for IRBs).

What the research has not shown is just as important: no study has demonstrated that acebilustat drains lymph, reduces Lipedema fat, or reverses fibrosis. Exploratory tissue findings in the published study are encouraging enough to keep studying — but encouraging findings are not established treatment effects, and nothing here is evidence for Lipedema.

Conceptual illustration only. It does not show a proven treatment effect.

Study 1: Published lower-limb study

Bowman and colleagues reported an open-label, prospective study at one site in Scientific Reports in 2026 (study record). Thirty people enrolled, and 23 completed 12 months; seven did not complete — four because of travel or inconvenience, three because of study-time limitations, and none because of an adverse event. Participants had chronic Stage II lymphedema, primarily lymphedema, not a diagnosed Lipedema study population.

Participants took 100 mg of acebilustat daily while continuing their established compression and self-care routines. There was no placebo group and no randomization. Researchers estimated limb volume from tape measurements using a formula; they did not directly measure fat volume.

The primary outcome was the summed volume of both lower limbs. The study reported an average reduction of about 1,012 mL, or 4.7% from baseline, over 12 months (primary results). That is a real, measurable change — and its meaning has two honest boundaries: it is not a one-leg figure, and it is not a liter of fat gone.

Other reported findings included:

• Caliper-measured skinfold thickness decreased by 1.1 mm at the calf and 1.6 mm at the thigh.
• Bioimpedance resistance (R0) increased by 13.8, a change the authors interpreted as consistent with less detectable extracellular fluid.
• Ultrasound measures and an exploratory AI image-analysis approach showed tissue changes. The AI analysis method itself is exploratory and not independently validated — this is a limitation of that specific analysis technique, not a statement that all ultrasound is unvalidated.
• LYMQOL, a quality-of-life measure, did not show a statistically significant improvement. A separate measure, LYMVAS, improved, but its formal validation is not complete.

(Outcomes section, published study)

Evidence grade: Emerging direct observational evidence. The changes are worth studying. Because there was no control group, the findings cannot establish that acebilustat caused them. Continued compression and self-care, measurement limits, and other factors matter when interpreting the results.

Side effects and exclusions in Study 1

Two participants had temporary interruptions after liver-enzyme elevations; values returned to baseline, and restarting did not reproduce the elevations during recorded follow-up. Two participants each had an episode of cellulitis. Other reported events included seven upper-respiratory infections, two cases of strep throat, and isolated reports of gout, bursitis, tinnitus, atrial fibrillation, traumatic injury, basal cell carcinoma, and small-intestinal bacterial overgrowth (safety reporting, published study).

The study does not establish which events were caused by the drug. No one withdrew because of an adverse event, but 23 completers are not enough to rule out uncommon or rare risks.

The study’s trial-specific exclusions included active cancer, a recent investigational-drug trial, thrombotic disorders, chronic kidney failure, anemia, low neutrophil counts, cardiac or liver dysfunction, pregnancy or nursing, prolonged QT, and eligibility for the separate upper-limb trial (exclusion criteria, study Methods). Monitoring included blood counts, metabolic and liver tests, and ECGs. These were criteria for that study, not confirmed contraindications or general medication guidance.

The study was funded by Stanford’s Innovative Medicines Accelerator and Celltaxis LLC (funding and author disclosures, published study). The authors reported that the funders had no role in study design, analysis, or the decision to submit the paper. Eric B. Springman, a coauthor, is a Celltaxis employee.

Study 2: The upper-arm HEAL trial

Stanford’s HEAL trial (NCT05203835) studied people ages 18–75 with unilateral Stage II arm lymphedema (Stanford trial listing; ClinicalTrials.gov record NCT05203835). The Stanford description says participants received placebo for approximately three months and acebilustat for approximately six months within a nine-month study-drug schedule, with the study blinded to participants. Compression and self-care continued.

Stanford reported on September 30, 2026, that analysis of the results was underway (Stanford Medicine news). We have not independently verified a published HEAL results report in this review (checked October 25, 2026), so we cannot say whether the drug was effective or what side-effect rates occurred in HEAL.

The Stanford and NCI trial listings differ on the affected-to-unaffected limb-volume eligibility cutoff. We are omitting the numeric cutoff rather than choose one while the records disagree.

Eligibility and safety details in HEAL

The Stanford trial listing describes exclusions such as kidney or liver disease, clotting disorders, chronic infection in the affected limb, active or recent cancer treatment, pregnancy or nursing, a history of long-QT syndrome, substance misuse, and allergy to the drug. It also lists certain medicines that excluded participation.

The NCI listing gives screening thresholds, including creatinine above 2.5 mg/dL or eGFR below 30; AST or ALT above three times the upper limit of normal; bilirubin above twice the upper limit of normal; neutrophils below 1,500/mm³; hemoglobin below 9 g/dL; and QTcF above 430 ms for men or 450 ms for women. These are trial eligibility criteria, not general medical thresholds or instructions for any individual.

The Stanford listing also excluded certain co-treatments, including NSAIDs, prior therapeutic ketoprofen, statins, immunomodulators, zileuton, and montelukast. The trial’s statin rule required stopping statins at least two weeks before enrollment (Stanford eligibility listing). That was a trial rule, not medical advice. Do not stop or change prescribed medicines based on a study listing.

What a different-disease safety study can, and cannot, tell us

Acebilustat was also studied in 199 adults with cystic fibrosis in the 48-week EMPIRE-CF randomized trial (Elborn et al., 2021). That is a different disease and population, so its side-effect rates cannot be used to predict what people with lymphedema or Lipedema might experience.

The trial did not meet its main lung-function endpoint, and it did not show a statistically significant overall reduction in pulmonary exacerbations. In the active-treatment groups, some reported adverse events occurred at least five percentage points more often than with placebo. For example, headache was reported by 23.9% of the 50 mg group versus 10.6% of the placebo group; diarrhea by 13.4% versus 6.1%. Serious adverse events occurred in 38.8% and 40.9% of the active groups, compared with 31.8% of placebo participants. Discontinuations due to adverse events were 6.0%, 6.1%, and 3.0%, respectively (trial results).

Evidence grade: Indirect. This trial provides safety experience in cystic fibrosis, not a safety profile for lymphedema or Lipedema.

Lipedema, lipo-lymphedema, and later stages

Lipedema and lymphedema are not interchangeable, even though swelling or fluid-related symptoms may overlap. Lipo-lymphedema refers to Lipedema with coexisting lymphedema; it does not make research in one condition evidence for the other.

Neither acebilustat study tested treatment for Lipedema. The lower-limb study involved Stage II lymphedema, not a study of Stage 3–4 Lipedema. There is no evidence from these trials that acebilustat reduces Lipedema fat or treats Lipedema itself. A change in extracellular fluid would not be the same as a change in Lipedema fat, and the study does not show that compression can be abandoned.

For more background, see our guides to Your Lymphatic System, Made Simple and 15 Years of Lipedema Science.

Conceptual illustration: fluid and adipose tissue are shown separately; it is not a diagnostic image.

What comes next, and questions to ask

The most useful next step for the evidence is publication of the blinded HEAL results, with clear reporting of outcomes and safety. Longer-term research should include more varied lymphedema populations, people with lipo-lymphedema, and people living with later-stage conditions. Any future Lipedema-specific research would need to study that population directly.

If you are discussing swelling or treatment options with a qualified clinician, you might ask:

1. How are we distinguishing lymphedema from Lipedema, or identifying whether both are present?
2. What does my current care plan address, and what remains uncertain?
3. Is any research relevant to my diagnosis and circumstances?
4. Which medicines are established treatments for a particular condition, and which remain experimental?

These are questions for an informed conversation, not a reason to seek or change medication on your own. If you want more context on where Lipedema research stands overall, the 15 Years of Lipedema Science living article is a good place to keep reading.

What we know / What we don’t know / What to watch next

What we know: A small, uncontrolled Stanford study reported an average reduction of about 1,012 mL in summed lower-limb volume over 12 months, alongside continued compression and self-care, in Stage II lymphedema. Acebilustat is an experimental drug, not a marketed lymphedema treatment.

What we don’t know: Whether acebilustat caused those changes, whether the HEAL study showed benefit (no published results report had been independently verified in this review as of October 25, 2026), or whether any of this applies to Lipedema, lipo-lymphedema, or Stage 3–4 populations.

What to watch next: Verified HEAL results, transparent safety reporting, and research that directly includes the people and conditions it hopes to inform.

Built for bodies that don’t have the same capacity every day. Instead of asking your body to keep up with the plan, we help the plan adapt to the body. Education for Changing Capacity. Support for Everyday Life.

Sources

• Bowman C, et al. “Therapeutic selective leukotriene B4 antagonism for human lymphedema.” Scientific Reports 16, 30318 (2026). Article and abstract. DOI: 10.1038/s41598-026-67215-4.
• Stanford HEAL trial listing (NCT05203835): Stanford Center for Lymphatic and Venous Disorders; ClinicalTrials.gov primary record; National Cancer Institute listing.
• Stanford Medicine (September 30, 2026): research news on acebilustat, noting upper-limb results analysis underway. Background reporting, not an efficacy source.
• Elborn JS, et al. “EMPIRE-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.” Journal of Cystic Fibrosis (2021). Accessible accepted manuscript; PMC record. DOI: 10.1016/j.jcf.2021.08.007.
• Cystic Fibrosis Foundation: pipeline summary noting the CF development was discontinued.
• FDA expanded access: FDA information for Institutional Review Boards (used for the distinction between expanded-access/investigational use and marketing approval).